2023 World Conference on Lung Cancer (Posters)-P2.18. Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso)

P2.18. Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso) - PDF(Slides)

Back to course

Pdf Summary

The study, titled "Real-world Study on Efficacy of First-Line Nivolumab Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso)," aims to investigate the efficacy of the combination of nivolumab and ipilimumab in treating patients with unresectable or metastatic malignant pleural mesothelioma (MPM) in a real-world setting in Latin America. The study included patients from seven centers in Argentina and Colombia, treated between June 2017 and January 2023.<br /><br />The primary objective of the study was to describe the clinical characteristics of patients treated with the nivolumab-ipilimumab regimen in the first-line setting. The secondary objectives included assessing the response rate, progression-free survival, overall survival, and the prognostic value of the Lung Immune Prognostic Index (LIPI) score.<br /><br />The study found that the nivolumab-ipilimumab regimen demonstrated substantial clinical efficacy and survival benefit in the first-line treatment of unresectable or metastatic MPM. The efficacy of the regimen was consistent regardless of histology. The study also identified the LIPI score as a potential prognostic factor.<br /><br />According to the authors, this study represents the only available real-world evidence of the efficacy of the nivolumab-ipilimumab regimen in the first-line setting of MPM in Latin America. The combination therapy has previously shown significant efficacy compared to chemotherapy in this patient population, particularly in non-epithelioid histology.<br /><br />The study's findings contribute to the understanding of the real-world effectiveness of nivolumab and ipilimumab in the treatment of unresectable or metastatic MPM. Further research and continued monitoring of patients are warranted to validate these findings and optimize treatment outcomes for patients with MPM.

Asset Subtitle

Edgar Aguirre

Meta Tag

Speaker Edgar Aguirre

Topic Mesothelioma, Thymoma & Other Thoracic Tumors: Clinical

Keywords

Real-world Study

Efficacy

Nivolumab

Ipilimumab

Unresectable Malignant Pleural Mesothelioma

Latin America

Clinical Characteristics

Response Rate

Lung Immune Prognostic Index

Survival Benefit